Targeting ECM disrupts cancer progression

208Citations
Citations of this article
313Readers
Mendeley users who have this article in their library.

Abstract

Metastatic complications are responsible for more than 90% of cancer-related deaths. The progression from an isolated tumor to disseminated metastatic disease is a multistep process, with each step involving intricate cross talk between the cancer cells and their non-cellular surroundings, the extracellular matrix (ECM). Many ECM proteins are significantly deregulated during the progression of cancer, causing both biochemical and biomechanical changes that together promote the metastatic cascade. In this review, the influence of several ECM proteins on these multiple steps of cancer spread is summarized. In addition, we highlight the promising (pre-)clinical data showing benefits of targeting these ECM macromolecules to prevent cancer progression.

Cite

CITATION STYLE

APA

Venning, F. A., Wullkopf, L., & Erler, J. T. (2015). Targeting ECM disrupts cancer progression. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2015.00224

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free